Indonesia relocates residents due to Caesium-137 contamination; New York and California support Planned Parenthood against federal funding cuts; English doctors strike for job security and pay; US ...

The FDA approved of Blenrep in combination with bortezomib and dexamethasone (BVd) for adults with relapsed or refractory multiple myeloma who have received at least two prior therapies.

The FDA approved belantamab mafodotin-blmf in combination with bortezomib and dexamethasone for the treatment of certain ...

Bay Area biopharmaceutical company Alector, Inc. is cutting dozens of jobs after the reported flop of its most recent drug trial. According to a Worker Adjustment Retraining ...

FDA approves cancer drug belantamab mafodotin-blmf for relapsed multiple myeloma in combination with bortezomib and dexamethasone.

Patients with vs without diabetes demonstrated a higher risk for uUTI treatment failure, although the observed difference was unlikely to be clinically relevant.

The Food and Drug Administration yesterday delivered a split decision on GSK’s blood cancer drug Blenrep, approving its use ...

The antibody-drug conjugate, withdrawn from the market by GSK in 2022 after failing a confirmatory study, was approved ...

Three years after its global market withdrawal and months after a negative advisory committee vote, GSK can officially call it a comeback for its multiple myeloma drug Blenrep in the U.S., albeit w | ...

Sanofi has dropped its respiratory syncytial virus (RSV) vaccine for toddlers after the candidate underperformed in a phase 3 ...

The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.

(Alliance News) - GSK PLC said Thursday its drug Blenrep has been approved by the US Food & Drug Administration for the treatment of adults with relapsed or refractory multiple myeloma, the third most ...